Phillips, Kelly-AnneRegan, MeredithRibi, KarinFrancis, Prudence APuglisi, FabioBellet, MeritxellSpazzapan, SimonKarlsson, PerBudman, Daniel RZaman, KhalilAbdi, Ehtesham ADomchek, Susan MFeng, YangPrice, Karen NCoates, Alan SGelber, RichardMaruff, PaulBoyle, FrancesForbes, John FAhles, TimFleming, Gini FBernhard, Jürg2017-05-012016Phillips, K., M. M. Regan, K. Ribi, P. A. Francis, F. Puglisi, M. Bellet, S. Spazzapan, et al. 2016. “Adjuvant ovarian function suppression and cognitive function in women with breast cancer.” British Journal of Cancer 114 (9): 956-964. doi:10.1038/bjc.2016.71. http://dx.doi.org/10.1038/bjc.2016.71.http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630717Background: To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer. Methods: The Suppression of Ovarian Function (SOFT) trial randomised premenopausal women with hormone receptor-positive breast cancer to 5 years adjuvant endocrine therapy with tamoxifen+OFS, exemestane+OFS or tamoxifen alone. The Co-SOFT substudy assessed objective cognitive function and patient reported outcomes at randomisation (T0), and 1 year later (T1); the primary endpoint was change in global cognitive function, measured by the composite objective cognitive function score. Data were compared for the pooled tamoxifen+OFS and exemestane+OFS groups vs the tamoxifen alone group using the Wilcoxon rank-sum test. Results: Of 86 participants, 74 underwent both T0 and T1 cognitive testing; 54 randomised to OFS+ either tamoxifen (28) or exemestane (26) and 20 randomised to tamoxifen alone. There was no significant difference in the changes in the composite cognitive function scores between the OFS+ tamoxifen or exemestane groups and the tamoxifen group (mean±s.d., −0.21±0.92 vs −0.04±0.49, respectively, P=0.71, effect size=−0.20), regardless of prior chemotherapy status, and adjusting for baseline characteristics. Conclusions: The Co-SOFT study, although limited by small samples size, provides no evidence that adding OFS to adjuvant oral endocrine therapy substantially affects global cognitive function.en-USbreast cancerovarian functioncognitive functionquality of lifepremenopausalGnRH agonisttamoxifenexemestaneJournal Article2017-05-0110.1038/bjc.2016.71